Firma Immunic, Autor bei PR-Web

Immunic, Inc. Reports Second Quarter 2021 Financial Results and Highlights Recent Activity

Posted on 6. August 202113. December 2023 by Firma Immunic Posted in General Tagged 4sc, caldose, cancer, gtthe, immunic, imu, ltem, ltli, ltp, ltstrong, ltul, quotdisc, rrms, thymocyte, with

– Received FDA Clearance to Initiate Twin IMU-838 Phase 3 ENSURE Trials in Relapsing-Remitting Multiple Sclerosis and Supportive Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis – – Reported In Vitro Data Showing That IMU-935 May Inhibit the Generation of […]

Immunic, Inc. Announces Closing of $45.0 Million Public Offering

Posted on 20. July 202113. December 2023 by Firma Immunic Posted in General Tagged aegis, clinical, financial, fiscal, immunic, immunic's, imu, prospectus, report, revenue, roth, sandler, securities, statements, with

Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the closing of an underwritten public offering of 4,500,000 shares of its common […]

Immunic, Inc. Announces Pricing of $45 Million Public Offering of Common Stock

Posted on 15. July 202113. December 2023 by Firma Immunic Posted in General Tagged aegis, clinical, financial, fiscal, immunic, immunic's, imu, prospectus, report, revenue, roth, sandler, securities, statements, with

Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of 4,500,000 shares of its […]

Immunic, Inc. Announces Proposed Public Offering of Common Stock

Posted on 15. July 202113. December 2023 by Firma Immunic Posted in General Tagged clinical, financial, fiscal, immunic, immunic's, imu, market, prospectus, report, revenue, risks, sandler, securities, statements, with

Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that it intends to offer and sell shares of its common stock […]

Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

Posted on 1. July 202113. December 2023 by Firma Immunic Posted in Research / Development Tagged brain, calvid, dosing, immunic, immunic's, imu, market, neurofilament, patients, ppms, revenue, rrms, statements, unblinded, with

. – Phase 3 ENSURE Program in Relapsing-Remitting Multiple Sclerosis (RRMS) Comprises Twin Studies Evaluating Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo, Intended to Provide Straightforward Path to Regulatory Approval – Supportive Phase 2 CALLIPER Trial in Progressive Multiple […]

Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel

Posted on 1. June 202113. December 2023 by Firma Immunic Posted in Research / Development Tagged clinical, fiscal, immunic, immunic's, imu, market, mba, merck, new, project, report, revenue, securities, statements, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, announced the appointment of Inderpal Singh as General Counsel, effective today. In his new role, Mr. Singh […]

Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent Activity

Posted on 6. May 202113. December 2023 by Firma Immunic Posted in General Tagged 4sc, caldose, calvid, fiscal, immunic, immunic's, imu, market, patients, revenue, rrms, statements, unblinded, vaccines, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced financial results for the first quarter ended March 31, 2021 and highlighted recent activity. "Our clinical program […]

Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838

Posted on 31. March 202113. December 2023 by Firma Immunic Posted in General Tagged 4sc, cancer, domatinostat, fiscal, immunic, immunic's, imu, market, revenue, royalties, rrms, securities, statements, ulcerative, with

Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, and 4SC AG (FSE Prime Standard: VSC), today announced the signing of an agreement under which Immunic […]

Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent Activity

Posted on 26. February 202113. December 2023 by Firma Immunic Posted in Research / Development Tagged caldose, calvid, dosing, immunic, immunic's, imu, liver, market, patients, revenue, rrms, statements, syndrome, unblinded, with

Phase 3 Program of IMU-838 in Relapsing-Remitting Multiple Sclerosis Expected to Begin in the Second Half of 2021 Reported Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis Announced Main Analysis of Phase […]

Immunic, Inc. Added to NASDAQ Biotechnology Index

Posted on 14. December 202013. December 2023 by Firma Immunic Posted in Research / Development Tagged clinical, etf, etfs, fiscal, ibb, immunic, immunic's, imu, index, ishares, market, revenue, securities, statements, with

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective […]